Latest news with #PremierPartners
National Post
6 days ago
- Business
- National Post
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
Article content Sorry, your browser doesn't support embedded videos. Article content FREMONT, Calif. — Celltrio®, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. Article content The new funding will accelerate the global commercialization of RoboCell®, Celltrio's flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities, expand commercial operations across North America, Europe, and Asia and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories. Article content 'This investment marks a major milestone for Celltrio and validates our mission to streamline, scale, and standardize cell manufacturing through automation,' said Charlie Duncheon, CEO of Celltrio. 'We are thrilled to partner with Premier Partners, who share our vision of transforming the future of cell-based therapies with next-generation automation solutions.' Article content 'We are highly impressed by Celltrio's customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation,' said Jay Song, CEO of Premier Partners. 'We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide.' Article content About Celltrio® Article content Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs. Learn more at Article content About Premier Partners Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content Article content Article content
Yahoo
6 days ago
- Business
- Yahoo
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
FREMONT, Calif., June 17, 2025--(BUSINESS WIRE)--Celltrio®, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. The new funding will accelerate the global commercialization of RoboCell®, Celltrio's flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities, expand commercial operations across North America, Europe, and Asia and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories. "This investment marks a major milestone for Celltrio and validates our mission to streamline, scale, and standardize cell manufacturing through automation," said Charlie Duncheon, CEO of Celltrio. "We are thrilled to partner with Premier Partners, who share our vision of transforming the future of cell-based therapies with next-generation automation solutions." "We are highly impressed by Celltrio's customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation," said Jay Song, CEO of Premier Partners. "We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide." About Celltrio® Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs. Learn more at About Premier Partners Premier Partners is a leading investment firm specializing in growth equity and growth buyout investments. The firm focuses on rapidly growing sectors, particularly within the healthcare industry, and targets middle-market opportunities globally. Premier Partners has managed approximately $2.9 billion in assets and is supported by an experienced management team with deep industry expertise. Learn more at View source version on Contacts Media Contact: Cathleen LarsonMarketing DirectorBD@
Business Wire
6 days ago
- Business
- Business Wire
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
FREMONT, Calif.--(BUSINESS WIRE)--Celltrio®, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. Celltrio is redefining cell culturing and cell & gene therapy automation — powered by a $15 million strategic investment Share The new funding will accelerate the global commercialization of RoboCell®, Celltrio's flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities, expand commercial operations across North America, Europe, and Asia and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories. 'This investment marks a major milestone for Celltrio and validates our mission to streamline, scale, and standardize cell manufacturing through automation,' said Charlie Duncheon, CEO of Celltrio. 'We are thrilled to partner with Premier Partners, who share our vision of transforming the future of cell-based therapies with next-generation automation solutions.' 'We are highly impressed by Celltrio's customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation,' said Jay Song, CEO of Premier Partners. 'We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide.' About Celltrio® Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs. Learn more at About Premier Partners Premier Partners is a leading investment firm specializing in growth equity and growth buyout investments. The firm focuses on rapidly growing sectors, particularly within the healthcare industry, and targets middle-market opportunities globally. Premier Partners has managed approximately $2.9 billion in assets and is supported by an experienced management team with deep industry expertise. Learn more at
South China Morning Post
29-05-2025
- Business
- South China Morning Post
Hong Kong deepens ties with Middle East in Saudi Sukuk ETF's bullish debut
Hong Kong is taking another big step to strengthen financial-market linkages with the Middle East with the launch of Asia's first exchange-traded fund (ETF) tracking Saudi Arabia's Islamic government bonds, or sukuk. The ETF, called Premia BOCHK Saudi Arabia Government Sukuk ETF, started trading on the Hong Kong stock exchange on Thursday, giving local investors access to the world's second-largest market for Shariah-compliant debt securities. The ETF trades in Hong Kong dollars under code 3478 and in US dollars under code 9478. The fund tracks the performance of the iBoxx Tadawul Government and Agencies Sukuk Index, and includes only investment-grade sukuk issued by the Saudi government or its agencies and denominated in Saudi riyals or US dollars, according to a statement. The ETF jumped 1.4 per cent to HK$82.20 and 1 per cent to US$10.44 as of 10.37am local time. The ETF was launched by Premier Partners, a home-grown ETF provider, and BOCHK Asset Management, a unit of China's third-biggest lender Bank of China. HSBC will provide cross-border fund services in both financial markets, the statement showed. 'The idea is to have a range of hot offerings' that comply with their Islamic faith, Financial Secretary Paul Chan Mo-po says. Photo: Jonathan Wong 'There is a huge market in Islamic finance, and there are a lot of discussions that can be held between the market participants and our Islamic community,' Financial Secretary Paul Chan Mo-po said at the Capital Market Forum on Thursday. 'The idea is to have a range of hot offerings that comply with their beliefs and their regulatory requirements, and the sky is the limit.'
